By
Drug Target Review2024-02-13T16:00:51
Researchers have identified key differences between HSV-1 and HSV-2 and have developed monoclonal antibodies that could treat neonatal infections.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-04T07:05:00Z
Author Graham Craig
2026-05-22T07:38:00Z
Contributor Dr Helen Bright, By Drug Target Review
2023-03-03T14:06:14
Sponsored by Bio-Techne
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2025-04-22T14:58:00
Sponsored by Takara Bio USA
Site powered by Webvision Cloud